AI Overview

Un contrat attribué directement pour des consommables exclusifs utilisés dans les tests moléculaires du VPH sur les plateformes Cobas existantes pour le Programme provincial de dépistage du cancer du col de l'utérus.

Information de base

Numéro de Référence

00004798053

Organisation émettrice

Provincial Health Services Authority BC

Type d’appel d’offres

AI - Avis d’intention (Informel)

Numéro d’appel d’offres

PHSA 18015

Titre

Products related to Provincial Cervical Cancer Screening Program

Code d’identité d’origine

SCRIBE

Détails

Emplacement

Colombie Britannique

Type d’achat

Non-mentionné

Dates

Publication

2025-11-18 07h47:00 HNE

Date de fermeture

2025-11-27 17h00:00 HNE

Information du contact

Mahsa Sadeghi

604-297-9745

mahsa.ardebili@phsa.ca

Description

File # PHSA 18015
NOI Title: Products related to Provincial Cervical Cancer Screening Program
Provincial Health Services Authority

Notice is hereby given that Provincial Health Services Authority (“PHSA”) , intends to directly award a Contract to the following supplier to provide proprietary consumables used for high-volume HPV molecular testing on existing Cobas 6800 and Cobas 8800 platforms for Cervical Cancer Screening Lab (CCSL) for a term of up to five (5) years at an estimated annual value of $4,000,000.

Roche Diagnostics
201 Armand-Frappier Blvd
Laval, Quebec H7V 4A2 Canada

In accordance with applicable trade agreements, PHSA has chosen not to proceed with a competitive process for the following reason:
•the goods or services can be supplied only by the selected supplier and no alternative or substitute exists for the following reason:
(a)due to an absence of competition for technical reasons

BC Cancer utilizes Roche Cobas 6800 and Cobas 8800 analyzers for provincial primary HPV testing. The Roche HPV Amplification/Detection kits are the only clinically validated kit with integrated internal controls that may be used on the Cobas instruments already in place. Transitioning to a new platform would require replacement of existing analyzers, re-validation of the full testing workflow, retraining of staff, and would exacerbate existing testing backlogs, resulting in significant cost and clinical risk. Given these factors, no alternative supplier can meet the Provincial Cervical Cancer Screening Program’s clinical, technical, and capacity requirements without substantial additional cost, risk, and disruption to patient care.

Vendors who wish to challenge this decision should submit a detailed written objection for the attention of Mahsa Sadeghi, by email before 2:00pm Pacific Time, November 27, 2025. PHSA will review any and all issues received by this date and provide due consideration to each objection.
Please Reference File: # PHSA 18015 on all written correspondence.

Afficher davantage

Dérogation All amendments to the associated notice, including amended documents, plans and specifications (where applicable), are issued on bcbid.gov.bc.ca. MERX asks that you refer to bcbid.gov.bc.ca notice for these amendments. MERX stipulates that potential bidders may also be required to register with the buying authority as a bidder/plan taker. The contact information can be found within the notice abstract.